Source study found

Story checked

Distinct EFEMP1 variants cause different forms of vision loss (opens in a new tab)

news-medical.net · 2026-09-11

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study. 2 other points were not covered by the paper.

4 supported
2 overstated
2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Distinct EFEMP1 variants cause different forms of vision loss

news-medical.net · 2026-09-11

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Two of eight claims overstate the study. Four of eight check out. Two claims the study doesn't address.

4 supported
2 overstated
2 not covered

Open claim evidence

The source study

Widening the Spectrum of Disease Expression due to Heterozygous Variants in EFEMP1

JAMA Ophthalmology · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8OverstatedThe two different conditions are caused by two different variants in the same gene, with the new condition linked to p.Arg140Trp in EFEMP1.View evidenceHide evidence

Why this verdict

The p.Arg345Trp variant is described as causing canonical DHRD/ML, and p.Arg140Trp segregated with disease in three families. However, the story’s wording that the newly described condition is “caused” by p.Arg140Trp gives stronger causal certainty than the abstract-level case-series/segregation evidence supports. Framed as linked or associated, it would be supported.

Study evidence

The EFEMP1 p.Arg140Trp variant segregated with disease in all three unrelated families studied.

Study evidence

The comparator patient/family with canonical DHRD/ML (EFEMP1 p.Arg345Trp) had normal light- and dark-adapted visual function outside the central 10° and exhibited an increasing delay in rod recovery kinetics toward the fovea.

Claim 2 of 8OverstatedThe newly described disease starts slowly in the periphery of the retina, with preserved vision for much of life before peripheral vision and low-light vision worsen.View evidenceHide evidence

Why this verdict

The profile supports late-onset, predominantly peripheral degeneration, relative central visual acuity/macular sparing, nyctalopia, and peripheral rod dysfunction. But the story adds a longitudinal disease-course narrative—“starts slowly,” preserved vision for much of life, then worsening—that is stronger than the cross-sectional abstract-level case-series evidence directly establishes.

Study evidence

The EFEMP1 p.Arg140Trp variant segregated with disease in all three unrelated families studied.

Claim 3 of 8Not coveredThe new condition occurs due to a buildup of abnormally thick material between the eye's cells.View evidenceHide evidence

Why this verdict

The abstract-level profile does not describe a mechanism involving buildup of abnormally thick material between eye cells, nor does it establish that such buildup causes the condition. This mechanistic causal claim cannot be verified from the supplied abstract-depth profile.

Claim 4 of 8Not coveredThe work was published in JAMA Ophthalmology and began with a clinical description of a U.S. family in 1998 before expanding to multiple European families.View evidenceHide evidence

Why this verdict

The profile supports an enrollment/study span beginning in 1998 and the involvement of Philadelphia, Basel, and Prague clinics. However, it does not verify the publication venue, that the work “began with a clinical description of a U.S. family,” or the specific chronology of later expansion to European families. These details are not verifiable from the supplied abstract-depth profile.

Study evidence

The EFEMP1 p.Arg140Trp variant segregated with disease in all three unrelated families studied.

Claim 5 of 8SupportedScientists identified a new vision condition linked to a gene already connected to a different vision-loss disease.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that EFEMP1 was already connected to canonical DHRD/ML via p.Arg345Trp and that this paper defines a distinct phenotype associated with another EFEMP1 variant, p.Arg140Trp, across multiple families.

Study evidence

The EFEMP1 p.Arg140Trp variant segregated with disease in all three unrelated families studied.

Study evidence

Claim 6 of 8SupportedThe previously identified EFEMP1-related disease causes loss of central vision, while the newly described condition affects peripheral and night vision.View evidenceHide evidence

Why this verdict

The profile supports the contrast in topography: p.Arg140Trp is described as late-onset, predominantly peripheral retinal degeneration with preferential rod dysfunction/nyctalopia and relative macular sparing, while the p.Arg345Trp DHRD/ML comparator had preserved function outside the central 10° and rod-recovery delay concentrated toward the fovea. The story’s simplified central-versus-peripheral framing is consistent with the abstract evidence.

Study evidence

The EFEMP1 p.Arg140Trp variant segregated with disease in all three unrelated families studied.

Study evidence

Claim 7 of 8SupportedThree unrelated families in different countries sharing the p.Arg140Trp variant were studied and compared with a different family carrying p.Arg345Trp, which is associated with the already known central-vision condition.View evidenceHide evidence

As statedthree unrelated families

Why this verdict

The profile states that participants included three unrelated families with EFEMP1 p.Arg140Trp and one comparator family/patient with canonical DHRD/ML caused by p.Arg345Trp. It also notes multi-institutional inherited retinal disease clinics in Philadelphia, Basel, and Prague, supporting the story’s international/multi-family framing at abstract depth.

Study evidence

The EFEMP1 p.Arg140Trp variant segregated with disease in all three unrelated families studied.

Study evidence

Claim 8 of 8SupportedResearchers said slow recovery of vision when transitioning from light to dark may be a useful functional marker, even when retinas still look structurally intact.View evidenceHide evidence

Why this verdict

The profile supports that delayed rod-mediated dark adaptation and severe peripheral rod dysfunction can be detected at loci without visible atrophy or outer nuclear layer loss on OCT, and in some carriers despite normal fundus appearance and 20/20 acuity. The story’s functional-marker framing is consistent with that evidence.

Study evidence

The EFEMP1 p.Arg140Trp variant segregated with disease in all three unrelated families studied.

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

The paper includes a p.Arg345Trp DHRD/ML comparator family/patient showing a contrasting central functional topography, but the comparator evidence is limited to a single comparator family/patient at abstract depth.
The story mentions comparison with a different p.Arg345Trp family and the central-versus-peripheral contrast, but it does not flag the limitation that the comparator observations rely on only one comparator family/patient.
From case series comparator arm

4 things the story did carry across

The paper’s primary evidence is a multi-institutional family-based case series of three unrelated families with EFEMP1 p.Arg140Trp, including segregation assessment and multimodal retinal phenotyping.
The p.Arg140Trp phenotype is described as late-onset, predominantly peripheral retinal degeneration with preferential rod dysfunction, delayed dark adaptation, nyctalopia, and relative sparing of central acuity and macular structure.
Functional abnormalities, especially delayed rod-mediated dark adaptation, may be detectable before visible structural loss on OCT or fundus examination at tested loci.
Small sample size, case-series design, clinic-based ascertainment, and lack of population-level frequency, penetrance, quantitative effect-size, or full statistical detail limit generalizability.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDefine and characterize the anatomical and functional phenotype associated with the non-canonical EFEMP1 p.Arg140Trp (c.418C>T) variant across multiple families, including segregation with disease and topographic patterns of retinal dysfunction/degeneration.Family-based case series; segregation assessment with multimodal retinal phenotypingExpand

In plain English

Multi-institutional case series of 3 unrelated families reports that heterozygosity for EFEMP1 p.Arg140Trp (c.418C>T) segregates with a late-onset, predominantly peripheral retinal degeneration characterized by preferential rod dysfunction. Affected carriers showed delayed rod-mediated dark adaptation kinetics and severe peripheral rod dysfunction on topographically matched testing, sometimes at retinal loci without visible outer nuclear layer loss, while central visual acuity and macular structure were relatively spared. A comparator family with canonical DHRD/ML (EFEMP1 p.Arg345Trp) exhibited a distinct functional topography.

Key findings

The EFEMP1 p.Arg140Trp variant segregated with disease in all three unrelated families studied.
In one family, heterozygous carriers (4/4 carriers among five at-risk relatives tested) had delayed rod-mediated dark adaptation kinetics despite best-corrected visual acuity of 20/20 and normal fundus appearance; the single noncarrier had normal imaging and function.

What this piece can’t prove

Small sample size (three families) and case-series design limit generalizability and preclude estimation of penetrance or population-level effect sizes.
Potential ascertainment bias inherent to clinic-based case series and referral of symptomatic individuals.
Comparative observations rely on a single comparator family/patient with canonical DHRD/ML within the same report.

1 further detail could not be confirmed from the summary.

2human in vivoContrast the p.Arg140Trp phenotype with canonical DHRD/ML caused by EFEMP1 p.Arg345Trp using a comparator family/patient to highlight distinct topography and functional signatures.case series comparator armExpand

In plain English

A single comparator family/patient with canonical DHRD/ML due to EFEMP1 p.Arg345Trp was phenotyped alongside families with EFEMP1 p.Arg140Trp. The comparator showed preserved light- and dark-adapted visual function outside the central 10° and an increasing delay in rod recovery kinetics approaching the fovea, based on imaging and functional testing described for the case series.

Key findings

The comparator patient/family with canonical DHRD/ML (EFEMP1 p.Arg345Trp) had normal light- and dark-adapted visual function outside the central 10° and exhibited an increasing delay in rod recovery kinetics toward the fovea.